Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.82

Posted by Francis Steltz on Aug 5th, 2026

Gilead Sciences logo Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) announced a quarterly dividend on Tuesday, August 4th. Stockholders of record on Tuesday, September 15th will be given a dividend of 0.82 per share by the biopharmaceutical company on Tuesday, September 29th. This represents a c) annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th.

Gilead Sciences has increased its dividend payment by an average of 0.0%per year over the last three years and has increased its dividend every year for the last 10 years. Gilead Sciences has a payout ratio of 38.5% indicating that its dividend is sufficiently covered by earnings. Analysts expect Gilead Sciences to earn $9.73 per share next year, which means the company should continue to be able to cover its $3.28 annual dividend with an expected future payout ratio of 33.7%.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $135.94 on Wednesday. The business has a 50 day moving average of $129.58 and a 200-day moving average of $136.11. Gilead Sciences has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a market capitalization of $168.78 billion, a P/E ratio of 18.52 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.26) by $0.51. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same period last year, the company earned $2.01 EPS. The firm’s revenue was up 10.6% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences will post -0.78 earnings per share for the current year.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Gilead reported second-quarter revenue of $7.8 billion, up 10.6% year over year and above the $7.4 billion consensus estimate. Its $6.75 per-share loss was narrower than analysts’ expected loss of approximately $7.07–$7.26. Gilead Q2 Results
Positive Sentiment: HIV remained the primary growth driver. Product sales excluding Veklury rose 10% to $7.6 billion, while management raised its 2026 HIV growth outlook to 9%–10%. PrEP sales, including the newer Yeztugo product, reportedly doubled to about $1 billion, supporting the possibility of a durable HIV growth engine. Gilead Raises HIV Outlook
Positive Sentiment: Cantor Fitzgerald reaffirmed its “overweight” rating with a $155 price target, while Needham reaffirmed its “buy” rating and set a $170 target. The recommendations imply meaningful upside from recent trading levels. Analyst Ratings via Benzinga
Positive Sentiment: The California Supreme Court ruled in Gilead’s favor in a case involving whether drugmakers must develop potentially safer alternatives to existing safe medicines, reducing a notable product-liability risk. California Supreme Court Ruling
Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, or $3.28 annualized, yielding approximately 2.4%. The dividend is payable September 29 to shareholders of record September 15.
Negative Sentiment: Veklury sales fell 81% year over year, prompting Gilead to lower its full-year outlook for the COVID-19 treatment. The company also swung from $2.01 of earnings per share a year earlier to a quarterly loss as acquisition-related costs and R&D spending increased. Veklury and R&D Costs
Negative Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $1.95 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, and he retained more than 592,000 shares, limiting its significance as a bearish signal.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.